Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis
Little is known about the involvement of cytokines in the pathogenesis of primary progressive (PP) multiple sclerosis (MS). We evaluated in this cross-sectional study whether IL-18, IL-12p35, IL-12p40, TNF-α, IFN-γ, IL-10, IL-4, TGF-β, IL-12Rβ1, and IL-12Rβ2 mRNA expression in unstimulated white blo...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimmunology 2001-11, Vol.120 (1), p.152-160 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 160 |
|---|---|
| container_issue | 1 |
| container_start_page | 152 |
| container_title | Journal of neuroimmunology |
| container_volume | 120 |
| creator | van Boxel-Dezaire, A.H.H Smits, M van Trigt-Hoff, S.C.J Killestein, J van Houwelingen, J.C Polman, C.H Nagelkerken, L |
| description | Little is known about the involvement of cytokines in the pathogenesis of primary progressive (PP) multiple sclerosis (MS). We evaluated in this cross-sectional study whether IL-18, IL-12p35, IL-12p40, TNF-α, IFN-γ, IL-10, IL-4, TGF-β, IL-12Rβ1, and IL-12Rβ2 mRNA expression in unstimulated white blood cells showed significant differences between relapsing–remitting (RR), secondary progressive (SP) and PP MS patients, and healthy controls. All clinical subtypes showed unique mRNA expression patterns as compared to the controls. Both RR and SP patients displayed increased levels of IL-12p40, IL-18, and TGF-β mRNA compared to controls, whereas PP patients showed only increased IL-18 mRNA levels. Both in PP and SP patients, IFN-γ and IL-10 mRNA were decreased compared to RR patients and controls. PP patients were unique in that they showed decreased IL-12Rβ1 mRNA. In conclusion, our data show that the assessment of cytokine (receptor) mRNA profiles is useful to discriminate between the different clinical subtypes and suggest that different cytokines are involved in the pathogenesis of PP MS as compared to RR and SP MS. |
| doi_str_mv | 10.1016/S0165-5728(01)00398-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72259029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572801003988</els_id><sourcerecordid>18345856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-676e9ec16f8708480978cb58c9b7642b1b09231e4476a3fe37a18aaa91046a123</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7rj6E5ScRA-tqSSdTk6yDH4sDAp-nEM6XS3R7nSbpJX592Z3Bj3upQqKp77el5CnwF4BA_X6Sw1t03Zcv2DwkjFhdKPvkR3ojjdacrhPdv-QC_Io5x-MQSukeUguAJSRQrAd-b4_luVniEhdHOj1oQFOE3pcy5Lo_PnjFR1C9inMIbqCtMfyBzHW4jhiwlion0IM3k00b305rphpiHTephLWCWn2E6Ylh_yYPBjdlPHJOV-Sb-_eft1_aA6f3l_vrw6NF4aXRnUKDXpQo-6YlpqZTvu-1d70nZK8h54ZLgCl7JQTI4rOgXbOGWBSOeDikjw_zV3T8mvDXOxc78dpchGXLduO89Ywbu4EQQvZ6lZVsD2Bvj6SE452rXK4dLTA7I0V9tYKe6OzZWBvrbC69j07L9j6GYf_XWftK_DmBGDV43fAZLMPGD0OoTpQ7LCEO1b8Bc4qmEE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18345856</pqid></control><display><type>article</type><title>Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van Boxel-Dezaire, A.H.H ; Smits, M ; van Trigt-Hoff, S.C.J ; Killestein, J ; van Houwelingen, J.C ; Polman, C.H ; Nagelkerken, L</creator><creatorcontrib>van Boxel-Dezaire, A.H.H ; Smits, M ; van Trigt-Hoff, S.C.J ; Killestein, J ; van Houwelingen, J.C ; Polman, C.H ; Nagelkerken, L</creatorcontrib><description>Little is known about the involvement of cytokines in the pathogenesis of primary progressive (PP) multiple sclerosis (MS). We evaluated in this cross-sectional study whether IL-18, IL-12p35, IL-12p40, TNF-α, IFN-γ, IL-10, IL-4, TGF-β, IL-12Rβ1, and IL-12Rβ2 mRNA expression in unstimulated white blood cells showed significant differences between relapsing–remitting (RR), secondary progressive (SP) and PP MS patients, and healthy controls. All clinical subtypes showed unique mRNA expression patterns as compared to the controls. Both RR and SP patients displayed increased levels of IL-12p40, IL-18, and TGF-β mRNA compared to controls, whereas PP patients showed only increased IL-18 mRNA levels. Both in PP and SP patients, IFN-γ and IL-10 mRNA were decreased compared to RR patients and controls. PP patients were unique in that they showed decreased IL-12Rβ1 mRNA. In conclusion, our data show that the assessment of cytokine (receptor) mRNA profiles is useful to discriminate between the different clinical subtypes and suggest that different cytokines are involved in the pathogenesis of PP MS as compared to RR and SP MS.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/S0165-5728(01)00398-8</identifier><identifier>PMID: 11694330</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Clinical subtypes ; Cross-Sectional Studies ; Cytokines ; Cytokines - genetics ; Disease Progression ; Female ; Humans ; interleukin 12 receptors ; Interleukin-10 - genetics ; Interleukin-12 - genetics ; Interleukin-18 - genetics ; Leukocytes - immunology ; Male ; Middle Aged ; Multiple Sclerosis - genetics ; Multiple Sclerosis - immunology ; Multiple Sclerosis - physiopathology ; Receptors, Interleukin - genetics ; Receptors, Interleukin-12 ; RNA, Messenger - metabolism ; Transforming Growth Factor beta - genetics</subject><ispartof>Journal of neuroimmunology, 2001-11, Vol.120 (1), p.152-160</ispartof><rights>2001 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-676e9ec16f8708480978cb58c9b7642b1b09231e4476a3fe37a18aaa91046a123</citedby><cites>FETCH-LOGICAL-c392t-676e9ec16f8708480978cb58c9b7642b1b09231e4476a3fe37a18aaa91046a123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165572801003988$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11694330$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Boxel-Dezaire, A.H.H</creatorcontrib><creatorcontrib>Smits, M</creatorcontrib><creatorcontrib>van Trigt-Hoff, S.C.J</creatorcontrib><creatorcontrib>Killestein, J</creatorcontrib><creatorcontrib>van Houwelingen, J.C</creatorcontrib><creatorcontrib>Polman, C.H</creatorcontrib><creatorcontrib>Nagelkerken, L</creatorcontrib><title>Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Little is known about the involvement of cytokines in the pathogenesis of primary progressive (PP) multiple sclerosis (MS). We evaluated in this cross-sectional study whether IL-18, IL-12p35, IL-12p40, TNF-α, IFN-γ, IL-10, IL-4, TGF-β, IL-12Rβ1, and IL-12Rβ2 mRNA expression in unstimulated white blood cells showed significant differences between relapsing–remitting (RR), secondary progressive (SP) and PP MS patients, and healthy controls. All clinical subtypes showed unique mRNA expression patterns as compared to the controls. Both RR and SP patients displayed increased levels of IL-12p40, IL-18, and TGF-β mRNA compared to controls, whereas PP patients showed only increased IL-18 mRNA levels. Both in PP and SP patients, IFN-γ and IL-10 mRNA were decreased compared to RR patients and controls. PP patients were unique in that they showed decreased IL-12Rβ1 mRNA. In conclusion, our data show that the assessment of cytokine (receptor) mRNA profiles is useful to discriminate between the different clinical subtypes and suggest that different cytokines are involved in the pathogenesis of PP MS as compared to RR and SP MS.</description><subject>Adult</subject><subject>Clinical subtypes</subject><subject>Cross-Sectional Studies</subject><subject>Cytokines</subject><subject>Cytokines - genetics</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>interleukin 12 receptors</subject><subject>Interleukin-10 - genetics</subject><subject>Interleukin-12 - genetics</subject><subject>Interleukin-18 - genetics</subject><subject>Leukocytes - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - genetics</subject><subject>Multiple Sclerosis - immunology</subject><subject>Multiple Sclerosis - physiopathology</subject><subject>Receptors, Interleukin - genetics</subject><subject>Receptors, Interleukin-12</subject><subject>RNA, Messenger - metabolism</subject><subject>Transforming Growth Factor beta - genetics</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoMo7rj6E5ScRA-tqSSdTk6yDH4sDAp-nEM6XS3R7nSbpJX592Z3Bj3upQqKp77el5CnwF4BA_X6Sw1t03Zcv2DwkjFhdKPvkR3ojjdacrhPdv-QC_Io5x-MQSukeUguAJSRQrAd-b4_luVniEhdHOj1oQFOE3pcy5Lo_PnjFR1C9inMIbqCtMfyBzHW4jhiwlion0IM3k00b305rphpiHTephLWCWn2E6Ylh_yYPBjdlPHJOV-Sb-_eft1_aA6f3l_vrw6NF4aXRnUKDXpQo-6YlpqZTvu-1d70nZK8h54ZLgCl7JQTI4rOgXbOGWBSOeDikjw_zV3T8mvDXOxc78dpchGXLduO89Ywbu4EQQvZ6lZVsD2Bvj6SE452rXK4dLTA7I0V9tYKe6OzZWBvrbC69j07L9j6GYf_XWftK_DmBGDV43fAZLMPGD0OoTpQ7LCEO1b8Bc4qmEE</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>van Boxel-Dezaire, A.H.H</creator><creator>Smits, M</creator><creator>van Trigt-Hoff, S.C.J</creator><creator>Killestein, J</creator><creator>van Houwelingen, J.C</creator><creator>Polman, C.H</creator><creator>Nagelkerken, L</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis</title><author>van Boxel-Dezaire, A.H.H ; Smits, M ; van Trigt-Hoff, S.C.J ; Killestein, J ; van Houwelingen, J.C ; Polman, C.H ; Nagelkerken, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-676e9ec16f8708480978cb58c9b7642b1b09231e4476a3fe37a18aaa91046a123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Clinical subtypes</topic><topic>Cross-Sectional Studies</topic><topic>Cytokines</topic><topic>Cytokines - genetics</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>interleukin 12 receptors</topic><topic>Interleukin-10 - genetics</topic><topic>Interleukin-12 - genetics</topic><topic>Interleukin-18 - genetics</topic><topic>Leukocytes - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - genetics</topic><topic>Multiple Sclerosis - immunology</topic><topic>Multiple Sclerosis - physiopathology</topic><topic>Receptors, Interleukin - genetics</topic><topic>Receptors, Interleukin-12</topic><topic>RNA, Messenger - metabolism</topic><topic>Transforming Growth Factor beta - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Boxel-Dezaire, A.H.H</creatorcontrib><creatorcontrib>Smits, M</creatorcontrib><creatorcontrib>van Trigt-Hoff, S.C.J</creatorcontrib><creatorcontrib>Killestein, J</creatorcontrib><creatorcontrib>van Houwelingen, J.C</creatorcontrib><creatorcontrib>Polman, C.H</creatorcontrib><creatorcontrib>Nagelkerken, L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Boxel-Dezaire, A.H.H</au><au>Smits, M</au><au>van Trigt-Hoff, S.C.J</au><au>Killestein, J</au><au>van Houwelingen, J.C</au><au>Polman, C.H</au><au>Nagelkerken, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>120</volume><issue>1</issue><spage>152</spage><epage>160</epage><pages>152-160</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Little is known about the involvement of cytokines in the pathogenesis of primary progressive (PP) multiple sclerosis (MS). We evaluated in this cross-sectional study whether IL-18, IL-12p35, IL-12p40, TNF-α, IFN-γ, IL-10, IL-4, TGF-β, IL-12Rβ1, and IL-12Rβ2 mRNA expression in unstimulated white blood cells showed significant differences between relapsing–remitting (RR), secondary progressive (SP) and PP MS patients, and healthy controls. All clinical subtypes showed unique mRNA expression patterns as compared to the controls. Both RR and SP patients displayed increased levels of IL-12p40, IL-18, and TGF-β mRNA compared to controls, whereas PP patients showed only increased IL-18 mRNA levels. Both in PP and SP patients, IFN-γ and IL-10 mRNA were decreased compared to RR patients and controls. PP patients were unique in that they showed decreased IL-12Rβ1 mRNA. In conclusion, our data show that the assessment of cytokine (receptor) mRNA profiles is useful to discriminate between the different clinical subtypes and suggest that different cytokines are involved in the pathogenesis of PP MS as compared to RR and SP MS.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>11694330</pmid><doi>10.1016/S0165-5728(01)00398-8</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5728 |
| ispartof | Journal of neuroimmunology, 2001-11, Vol.120 (1), p.152-160 |
| issn | 0165-5728 1872-8421 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72259029 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Clinical subtypes Cross-Sectional Studies Cytokines Cytokines - genetics Disease Progression Female Humans interleukin 12 receptors Interleukin-10 - genetics Interleukin-12 - genetics Interleukin-18 - genetics Leukocytes - immunology Male Middle Aged Multiple Sclerosis - genetics Multiple Sclerosis - immunology Multiple Sclerosis - physiopathology Receptors, Interleukin - genetics Receptors, Interleukin-12 RNA, Messenger - metabolism Transforming Growth Factor beta - genetics |
| title | Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T10%3A54%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytokine%20and%20IL-12%20receptor%20mRNA%20discriminate%20between%20different%20clinical%20subtypes%20in%20multiple%20sclerosis&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=van%20Boxel-Dezaire,%20A.H.H&rft.date=2001-11-01&rft.volume=120&rft.issue=1&rft.spage=152&rft.epage=160&rft.pages=152-160&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/S0165-5728(01)00398-8&rft_dat=%3Cproquest_cross%3E18345856%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18345856&rft_id=info:pmid/11694330&rft_els_id=S0165572801003988&rfr_iscdi=true |